Familial overexpression of β antithrombin caused by an Asn135Thr substitution

Blood

Volumn 93, Issue 12, 1999, Pages 4242-4247

  Bayston, T A ^b   Tripodi, A ^b   Mannucci, P M ^b   Thompson, E ^b   Ireland, H ^b   Fitches, A C ^b   Hananeia, L ^b   Olds, R J ^b   Lane, D A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTITHROMBIN DEFICIENCY; ARTICLE; CASE REPORT; FEMALE; GLYCOSYLATION; HUMAN; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEQUENCE ANALYSIS;

EID: 0033564273     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4242.412k02_4242_4247     Document Type: Article

References (20)

1. Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M: Antithrombin III mutation database: First update. Thromb Haemost 70:361, 1993
2. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J: Antithrombin mutation database: 2nd (1997) update. Thromb Haemost 77:197, 1997
3. Sas G, Blasko G, Banhegyi D, Jako J, Palos LA: Abnormal antithrombin III (Antithrombin III "Budapest") as a cause of a familial thrombophilia. Thromb Diathes Haemorrh 32:105, 1974
4. Finazzi G, Caccia R, Barbui T: Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases. Thromb Haemost 58:1094, 1987
5. Hultin MB, McKay J, Abildgaard U: Antithrombin Oslo: Type 1b classification of the first reported antithrombin-deficient family with a review of hereditary antithrombin variants. Thromb Haemost 59:468, 1988
6. Blajchman M, Austin R, Fernandez-Rachubinski F, Sheffield W: Molecular basis of inherited antithrombin deficiency. Blood 80:2159, 1992
7. Lane DA, Olds RJ, Conard J, Boisclair M, Bock SC, Hultin M, Abildgaard U, Ireland H, Thompson E, Sas G, Horrelou MH, Tamponi G, Thein SL: Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 90:2422, 1992
8. McKay EJ: A simple two-step procedure for the isolation of antithrombin from biological fluids. Thromb Res 21:375, 1991
9. Chowdhury V, Olds RJ, Lane DA, Pabinger I, Machin SJ, Ryan K, Bauer KA, Bhavani M, Abildgaard U, Finazzi G, Conard J, Castaman G, Mannucci P, Thein SL: Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol 84:656, 1993
10. Peterson CB, Blackburn MN: Isolation and characterisation of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 260:610, 1985
11. Brennan SO, George PM, Jordan RE: Physiological variant of antithrombin III lacks carbohydrate side chain at Asn 135. FEBS Lett 219:431, 1987
12. Erdsal-Badju E, Lu A, Peng X, Picard V, Zendehouh P, Tirk B, Bjork I, Olson ST, Bock SC: Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a β-like variant in baculovirus-infected insect cells. Biochem J 310:323, 1995
13. Picard V, Ersdal-Badju E, Bock SC: Partial glycosylation of antithrombin III asparagine 135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the β-antithrombin III isoform with enhanced heparin affinity. Biochemistry 34:8433, 1995
14. Bjork I, Olson ST, Shore JD: Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and the clotting proteinases, in Lane DA, Lindahl U (eds): Heparin: Chemical and Biological Properties, Clinical Applications. London, UK, Arnold, 1989, p 229
15. Turk B, Brieditis I, Bock S, Olson ST, Bjork I: The oligosaccharide side chain of α-antithrombin, absent in β-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry 36:6682, 1997
16. Carlson TH, Atencio AC, Simon TL: Comparison of the behaviour in vivo of two molecular forms of antithrombin III. Biochem J 225:557, 1985
17. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L: Heparan sulfate proteoglycans of the cardiovascular system. Specfic structures emerge but how is biosynthesis regulated? J Clin Invest 99:2062, 1997
18. Felcsh JS, Owen WG: Endogenous antithrombin associated with microvascular endothelium. Quantitative analysis in perfused rat hearts. Biochemistry 33:818, 1994
19. Witmer MR, Hatton MWC: Antithrombin-III-β associates more readily than antithrombin-III-α with uninjured and de-endothelialized aortic walls in vitro and in vivo. Arterioscler Thromb 11:530, 1991
20. Frebelius S, Isaksson S, Swedenborg J: Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform ATβ. Arterioscler Thromb Vasc Biol 16:1292, 1996